Jupiter Neurosciences (JUNS) Operating Leases (2023 - 2025)

Jupiter Neurosciences (JUNS) posted quarterly Operating Leases of $8507.0 for Q1 2025, down 59.96% quarter-over-quarter from $21247.0 in Q4 2024.

Jupiter Neurosciences (JUNS) Operating Leases (2023 - 2025) Analysis & Trends

Jupiter Neurosciences (JUNS) has reported Operating Leases for 3 consecutive years, with $8507.0 the latest figure, recorded in Q1 2025.

In Q1 2025, Operating Leases changed N/A year-over-year to $8507.0; the TTM figure through Mar 2025 stood at $8507.0 (changed N/A YoY), while the FY2024 annual figure was $21247.0, down 70.21% from the prior year.
Operating Leases eased to $8507.0 in Q1 2025 per JUNS's latest filing, from $21247.0 in the prior quarter.
Across five years, Operating Leases topped out at $71329.0 in Q4 2023 and bottomed at $8507.0 in Q1 2025.
Historically, Operating Leases has averaged $33761.0 across 3 years, with a median of $27604.0 in 2024.
On a YoY basis, Operating Leases climbed as much as 70.21% in 2024 and fell as far as 70.21% in 2024.
Jupiter Neurosciences' Operating Leases stood at $71329.0 in 2023, then slumped by 70.21% to $21247.0 in 2024, then tumbled by 59.96% to $8507.0 in 2025.
Business Quant data shows JUNS's Operating Leases at $8507.0 in Q1 2025, $21247.0 in Q4 2024, and $33961.0 in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Jupiter Neurosciences	3.37 Mn	1.85 Mn	21,064.00

Download Data